The 20 Most Disruptive Healthcare Solution providers The 20 Most Disruptive Healthcare Solution Provide | Page 14

biomarker information. Importantly, the technology enables
the storage of samples indefinitely for future analysis and
the microscopic imaging capabilities including confocal,
light sheet, and SPIM.
, ,
Revolutionizing the
treatment of
The workflow of this platform is very simple and includes:
Ø
, ,
cancer is our goal
Ø
Ø
Ø
ClearLight’s Ingenious Solution
ClearLight is developing a next generation instrument,
reagent and software platform for volumetric tissue
processing and 3D image analysis. It is developing this
solution by leveraging the revolutionary technology called
CLARITY, which is an acronym for Clear Lipid-exchanged
Acrylamide-hybridized Rigid Imaging/Immunostaining/In-
situ hybridization-compatible Tissue-hYdrogel.
“CLARITY is a novel approach that is innovative in both
function and utility, and has been applied broadly to the
field of neurobiology, primarily as a qualitative tool,” says
Dr. Goodman. The company believes in the technology as it
enables the formation of a hydrogel matrix (HM) by
crosslinking biological molecules to a 3D network of
hydrophilic polymers, followed by lipid removal to
generate a transparent and structurally intact tissue. This
tissue retains its original structural features, can be labeled
with macromolecules, and imaged without destruction of
the tissue morphology.
Another advantage of the CLARITY technology, is that it is
compatible with previously frozen, fresh, formalin-fixed,
and FFPE research and clinical human or rodent tissue. It is
non-destructive, and therefore fewer samples are required,
thus allowing recapitulation of spatial heterogeneity without
laborious sectioning and registering of samples. It is
compatible with standard nucleic acid and antibody
interrogation techniques. This technique also allows for
multiple interrogations of a single sample to increase 3D
Ø
Embedding the tissue in a hydrogel matrix
solution;
Removal of light scattering lipids that impede the
ability to image deeply within a tissue;
Multiplexed interrogation with directly or
indirectly fluorescently labeled antibodies or
nucleic acids to identify key structural and
microenvironment biomarkers and refractive index
matching;
Microscopic imaging of the tissues, using long
working distance objectives and either confocal,
light sheet, or SPIM;
3D image analysis using Artificial Intelligence
(AI) and machine learning techniques.
The development program of the company is a combination
of external software and hardware engineering contractors,
as well as strategic academic and business partnerships.
Team ClearLight
The internal team of ClearLight is comprised of a Director
of Operations, two Directors of Research and Development,
a Head of Lab Operations along with the CEO. In order to
keep costs to a minimum, the company operates primarily
with an extensive external network support that handle
human resources, IT, accounting & taxes, engineering,
animal facility CRO, marketing/website support, and legal
works (corporate and IP). It also has key academic
collaborations in the area of oncology and neuroscience.
Determined to Revolutionize the Future of Medicine
The mission of ClearLight is to revolutionize the
diagnostic, prognostic, and predictive treatment of disease
by enabling next generation technologies for non-
destructively and digitally analyzing diseased and normal
tissues in 3D. It predicts a similar future of this industry as
to that of the adoption of next generation sequencing (NGS)
into clinical decision making that took more than 20 years
and has now become a billion-dollar industry.
Dr. Goodman says, “We predict a similar steady trajectory
with